CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM moves into new building and issues inaugural bond

Almost a year after the topping-out ceremony in March 2019, the extension at the companies headquarters in Greifswald (Ziegelhof) is ready for occupancy; the employees are now gradually moving to the functional, elegant new building with state of the art equipped offices and meeting rooms; the company has invested around 7 million euros in the approximately 5,300 square meter office building - without government grants. At the same time, CHEPLAPHARM managed a financing coup of around 500 million euros on the international bond market last week.

"Based on the very good cooperation with our construction company OBAG, the completion of the new building was a 'precision landing', so that we were able to create modern and professional work opportunities for our numerous new employees in a short time," commented Sebastian F. Braun (CEO).

When planning the extension to which the employees are now moving, CHEPLAPHARM was geared to the guiding principles of regenerative resources and energy efficiency. Consequently, charging stations for e-cars and e-bikes for the new building have been installed. Furthermore, there are modern meeting rooms in the new construction, which can be flexibly adapted to different usage requirements: from internal meetings in small groups to larger groups with up to 30 people. Another highlight is the large roof terrace (200sqm): It can be used by employees for events, to linger during lunch breaks or to "chill out" after work.

In parallel with the completion of the expansion, CHEPLAPHARM last week managed to place a High Yield Bond in the amount of €500 million at 3,50% with international investors for the first time and with great success. The High Yield Bond will further optimize, diversify and sustainably secure the company's financing structure.

"You could not wish for a better start to the new year, because the transaction on the bond market ensures the long-term financing of CHEPLAPHARM in a sustainable and flexible manner. Moreover, we now have additional liquidity available to finance future M&A projects," said CFO Jens Rothstein, expressing his satisfaction with the company's latest financing coup.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)

Investor Relations topics

Back to top expand_less